ORG
CDMO Leaders Unite for Turn-key Drug Production
Contract Development and Manufacturing Organizations (CDMOs), pharmaceutical supply chain, advanced therapies, strategic partnerships, end-to-end services, technology innovation, market consolidation, and competitive advantage.
Exsilio Emerges from Stealth with $82 Million to Revolutionize Gene Therapy
Exsilio Therapeutics, Gene Therapy, Novel Approach, mRNA, Lipid Nanoparticle Delivery, Biotech Company, Genetic Medicine
Teladoc Research Highlights the Impact of AI-Powered ‘Nudges’ on Diabetes Management
Teladoc Health, AI-powered nudges, diabetes management, personalized health, predictive modeling, chronic condition management, virtual care
Merck KGaA Discontinues Xevinapant Program for Locally Advanced Head and Neck Cancer
Merck KGaA, Xevinapant, Head and Neck Cancer, Phase III Trial, Discontinuation, Cancer Treatment
Pfizer Secures Major Contract Over GSK for RSV Vaccine Supply in the UK
Pfizer, GSK, RSV vaccine, UK contract, Abrysvo, Arexvy
Alnylam Achieves Breakthrough in Heart Study with RNAi Therapy Vutrisiran
Alnylam, Vutrisiran, RNAi Therapy, Heart Study, ATTR Amyloidosis, Cardiomyopathy
UK Government Selects Pfizer Over GSK to Supply RSV Vaccine Doses
Pfizer, GSK, RSV vaccine, UK government, pharmaceutical companies, vaccine supply
Lilly’s Zepbound Shows Promise in Resolving Sleep Apnea in Obese Patients, Strengthening Case for Label Expansion
Zepbound, tirzepatide, sleep apnea, obesity, label expansion, Eli Lilly, SURMOUNT-OSA program, weight loss, FDA approval
Argenx’s Vyvgart Hytrulo Secures Second US Approval for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Vyvgart Hytrulo, Argenx, FDA Approval, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Autoimmune Disease, Peripheral Nervous System Disorder
FDA Approves Adagrasib (Krazati) with Cetuximab for KRAS G12C-Mutated Colorectal Cancer
Adagrasib, Krazati, Cetuximab, KRAS G12C, Colorectal Cancer, FDA Approval, Bristol Myers Squibb, Mirati Therapeutics, Amgen, Lumakras